Obesity in patients with non-ST-segment elevation acute coronary syndromes: results from the SYNERGY trial. Int J Cardiol. 2010;139:123 33. 809. Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled- release, phentermine plus topiramate combination on weight and asso- ciated comorbidities in overweight and obese adults (CONQUER): a randomised,placebo-controlled,phase3trial.Lancet.2011;377:1341 52. 810. Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-con- trolled, phase 3 extension study. Am J Clin Nutr. 2012;95:297 308. 811. Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96:3067 77. 812. Busetto L, De SF, Pigozzo S, et al. Long-term cardiovascular risk and coronary events in morbidly obese patients treated with laparoscopic gas- tric banding. Surg Obes Relat Dis. 2013. 813. Pantaleo MA, Mandrioli A, Saponara M, et al. Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib. BMC Cancer. 2012;12:231. 814. Ozturk B, Tacoy G, Coskun U, et al. Gemcitabine-induced acute coro- nary syndrome: a case report. Med Princ Pract. 2009;18:76 80. 815. Criscitiello C, Metzger-Filho O, Saini KS, et al. Targeted therapies in breast cancer: are heart and vessels also being targeted? Breast Cancer Res. 2012;14:209. 816. Chalubinski M, Wojdan K, Dorantowicz R, et al. Comprehensive insight into immune regulatory mechanisms and vascular wall determinants of atherogenesis - emerging perspectives of immunomodulation. Arch Med Sci. 2013;9:159 65. 817. American Heart Association. Get With the Guidelines. 2009. Available at: http://www.heart.org/HEARTORG/HealthcareResearch/ GetWithThe GuidelinesHFStroke/Get-With-The-Guidelines HFStroke_ UCM_001099_SubHomePage.jsp. Accessed August 28, 2014. 818. ASSENT-4 PCI Investigators. 